logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA).

Ashman says it's a significant first deal for them and provides third-party validation of its technology.

Quick facts: SkinBioTherapeutics PLC

Price: 14.5 GBX

AIM:SBTX
Market: AIM
Market Cap: £18.57 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: SkinBio signs commercial deal with chemical giant Croda

Headlines from the Proactive UK newsroom. SkinBioTherapeutics (LON:SBTX) has signed a commercial and manufacturing agreement for its Skinbiotix technology with speciality chemical giant Croda.  It is the first major deal for the product with Croda to design and manufacture a new active...

2 weeks, 2 days ago

RNS

Notice of AGM

1 week, 3 days ago

Final Results

1 week, 3 days ago

Commercial Agreement

2 weeks, 2 days ago

Holding(s) in Company

1 month ago

2 min read